Nanotechnology turns up heat on prostate tumors

Bathe a prostate tumor in metallic particles that preferentially move through permeable capillaries and into the tumor bed. Shine an infrared light on the particles. The metal, but not the tissue, absorbs infrared energy; as it heats, it destroys tumor cells. Tissue not in contact with the metal particles, ie, healthy tissue, is unaffected.

Related Videos

Related Content

Advertisement

March 21st 2025

Avoidance of prostate cancer screening linked to increased risk of PCSM

Hannah Clarke

“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 21st 2025

Money Matters: How to cope with market volatility in 2025

Jeff Witz, CFP

"If you determine you can invest in a volatile environment, the best approach is to do so over a period of time," writes Jeff Witz, CFP.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.

Related Content

Advertisement

March 21st 2025

Avoidance of prostate cancer screening linked to increased risk of PCSM

Hannah Clarke

“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 21st 2025

Money Matters: How to cope with market volatility in 2025

Jeff Witz, CFP

"If you determine you can invest in a volatile environment, the best approach is to do so over a period of time," writes Jeff Witz, CFP.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.